查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994342

基因分析市場：按產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Genetic Analysis Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因分析市值將達到 117.3 億美元，到 2026 年將成長到 125.9 億美元，到 2032 年將達到 209.4 億美元，複合年成長率為 8.62%。

主要市場統計數據
基準年 2025 117.3億美元
預計年份：2026年 125.9億美元
預測年份 2032 209.4億美元
複合年成長率 (%) 8.62%

清楚概述了技術成熟度、監管變化和業務擴張如何重新定義基因分析領域所有相關人員的優先事項和策略選擇。

在技​​術進步和醫療保健重點轉變的推動下，基因分析領域正進入科學成熟和商業性化加速發展的階段。近年來，定序處理能力顯著提升，單一樣本的處理時間大幅縮短。這使得更多臨床和研究應用案例得以從探索階段過渡到常規工作流程。同時，檢查室自動化和基於雲端的生物資訊學降低了規模化應用的門檻，使機構能夠在保證品質和可重複性的前提下處理更多樣本。

高通量技術的整合、監管對臨床效用的重視以及供應鏈的韌性如何改變競爭動態和策略重點。

基因分析生態系統正在發生根本性轉變，重塑價值創造的模式以及創新在整個價值鏈中的流動方式。高通量定序、先進的PCR技術和改進的微陣列平台等技術的融合，結合雲原生分析技術，建構了一個整合的流程，縮短了周轉時間，提高了診斷準確性。這使得檢查室和商業供應商能夠擴展其服務組合，並推行垂直整合策略，將儀器、耗材和資訊服務整合在一起。

了解關稅制度的變化如何影響整個基因分析生態系統的籌資策略、供應商多元化和本地生產決策。

主要經濟體關稅政策的變化可能會對檢查室、製造商和服務供應商的成本結構和採購決策產生重大影響。進口試劑、設備和特殊組件關稅的提高可能會增加直接接收成本，並造成價格壓力不均，從而扭曲國內外供應商之間的採購。為此，製造商可能會調整其全球籌資策略，將部分組裝流程轉移到更靠近需求中心的地方，或調整產品系列，優先考慮貿易條件有利的地區。

詳細的細分分析揭示了技術模式、應用、產品類型和最終用戶畫像如何共同塑造商業性通路和投資重點。

從細分市場的觀點來看，技術能力、客戶需求和商業化模式的交會點清晰可見，從而創造了差異化的機會。技術細分突顯了傳統平台與新興技術之間的互動。具體而言，微陣列在標靶基因型鑒定和人群研究中仍然發揮著重要作用；次世代定序(NGS) 推動了全面的基因組分析和新型應用；聚合酵素鏈鎖反應(PCR) 支持快速診斷和定量分析；而桑格定序則繼續為檢驗和特定定序任務做出貢獻。每條技術路徑都有其獨特的開發週期、法規考量和成本績效特徵，這些因素都會影響其應用軌跡。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和獨特機會正在影響戰略市場進入和供應鏈選擇。

全球基因分析市場的區域趨勢造就了不同的機會與風險。在美洲，成熟的醫療基礎設施和完善的報銷機制為先進的臨床應用、強勁的私人投資以及緊密的診斷檢查室和生物製藥合作夥伴網路提供了支持。這種環境有利於快速的臨床應用和商業化規模化，同時也吸引了人才和資本投向儀器和軟體相關的企業。

競爭格局洞察顯示，平台創新、整合服務和符合監管規定的合作夥伴關係如何決定領導地位和差異化。

基因分析領域的競爭格局反映了技術領先地位、綜合服務能力和策略夥伴關係關係的整合。領先的儀器製造商持續投資於提升處理能力、簡化操作流程以及完善耗材生態系統，以確保市場需求的持續成長。同時，專業服務供應商和定序中心正通過認證、快速週轉以及與臨床級服務相結合的生物資訊深度，為醫院和診斷檢查室提供差異化優勢。

為領導者提供切實可行的建議，以增強價值鏈韌性、加速臨床檢驗、擴展分析能力並開發靈活的價值創造經營模式。

產業領導者應優先採取一系列切實可行且影響深遠的措施，將策略意圖轉化為可衡量的成果。首先，實現關鍵試劑和組件供應商多元化，探索近岸外包和區域生產夥伴關係，以降低地緣政治和關稅風險，並增強供應鏈韌性。其次，將產品開發與臨床效用證據的取得結合。投資前瞻性檢驗試驗，與保險公司合作，並簡化報銷流程，以加速產品推廣應用。

我們高度透明的調查方法，結合了相關人員訪談、二手文獻整合和基於情境的分析，得出檢驗的策略見解和可操作的指南。

本分析的調查方法融合了與關鍵相關人員的對話、對二手文獻的回顧以及與監管和臨床指南的交叉比檢驗，以確保獲得可靠且可操作的見解。關鍵資訊來源包括與實驗室經理、研發經理、採購負責人和生物資訊專家進行結構化訪談，以了解實際操作情況、推廣應用障礙以及臨床檢驗的優先事項。這些定性觀點與近期同儕審查文獻、監管公告和專利趨勢的系統性回顧進行交叉比對，以檢驗技術進步和新興應用案例。

結論強調，要充分發揮基因分析的潛力，必須將嚴謹的證據生成、強大的營運系統和以客戶為中心的數位化能力結合。

總而言之，基因分析領域正處於強大的技術能力與複雜的商業性、監管和供應鏈現實的交匯點。定序、PCR 和自動化技術的進步使其在臨床和研究領域廣泛應用，但長期成功取決於能否證明其臨床效用、確保供應的連續性以及應對不同的區域法規結構。那些能夠整合高品質證據的創建、穩健的營運設計和以客戶為中心的數位化工具的機構，將建立永續的競爭優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基因分析市場：依產品類型分類

  • 消耗品
  • 裝置
  • 服務
  • 軟體

第9章 基因分析市場：依技術分類

  • 微陣列
  • 次世代定序
  • 聚合酵素鏈鎖反應
  • 桑格定序

第10章 基因分析市場：依應用領域分類

  • 臨床診斷
  • 遺傳性疾病
  • 感染疾病
  • 腫瘤學
  • 生殖醫學

第11章 基因分析市場：依最終使用者分類

  • 合約研究機構
  • 診斷檢測實驗室
  • 醫院
  • 製藥公司
  • 研究機構

第12章 基因分析市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 基因分析市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 基因分析市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基因分析市場

第16章：中國基因分析市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Beam Therapeutics Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenScript Biotech Corporation
  • Illumina, Inc.
  • Intellia Therapeutics, Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Sangamo Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C059E

The Genetic Analysis Market was valued at USD 11.73 billion in 2025 and is projected to grow to USD 12.59 billion in 2026, with a CAGR of 8.62%, reaching USD 20.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.73 billion
Estimated Year [2026] USD 12.59 billion
Forecast Year [2032] USD 20.94 billion
CAGR (%) 8.62%

An incisive overview of how technological maturation regulatory shifts and operational scaling are redefining priorities and strategic choices across genetic analysis stakeholders

The genetic analysis landscape has entered a period of accelerated scientific maturation and commercial evolution driven by converging technological advances and shifting healthcare priorities. Recent years have seen exponential improvements in sequencing throughput and reductions in per-sample processing time, enabling a wider set of clinical and research use cases to transition from exploratory stages into routine workflows. Concurrently, laboratory automation and cloud-enabled bioinformatics have lowered barriers to scale, giving institutions the ability to process higher volumes while maintaining quality and reproducibility.

These operational gains are complemented by a more nuanced regulatory environment that emphasizes analytical validity, clinical utility, and data governance. Stakeholders now operate within a context where ethical considerations, privacy frameworks, and payer expectations shape adoption pathways as strongly as raw technical capability. As a consequence, strategic choices around platform selection, partnership models, and talent development are increasingly defining competitive differentiation. Leaders who align investments with demonstrable clinical outcomes and robust compliance postures will be better positioned to capture long-term value.

How convergence of high-throughput technologies regulatory emphasis on clinical utility and supply chain resilience is shifting competitive dynamics and strategic priorities

Fundamental shifts in the genetic analysis ecosystem are remapping where value accrues and how innovation flows across the value chain. Technological convergence has brought together high-throughput sequencing, advanced PCR modalities, and improved microarray platforms with cloud-native analytics, creating integrated pipelines that reduce turnaround time and improve diagnostic resolution. This has enabled laboratories and commercial providers to expand service portfolios and pursue vertical integration strategies that combine instrumentation, consumables, and data services.

At the same time, payer scrutiny and outcome-based contracting are incentivizing the development of clinically actionable assays and companion diagnostics. As clinical utility takes center stage, companies are redirecting R&D investments toward indications with clear pathways to reimbursement and demonstrated patient benefit. Additionally, supply chain resilience has become a strategic imperative; disruptions and geopolitical forces have accelerated efforts to diversify sourcing, localize critical production, and build inventory and logistics flexibility. Together, these forces are transforming competitive dynamics and encouraging collaborations that span industry incumbents, academic centers, and specialist service providers.

Understanding how changes in tariff regimes influence procurement strategy supplier diversification and localized manufacturing decisions across the genetic analysis ecosystem

Tariff policy shifts in major economies can materially alter cost structures and procurement decisions across laboratories, manufacturers, and service providers. Increased tariffs on imported reagents, instruments, and specialized components raise direct landed costs and can create uneven pricing pressures that distort procurement between domestic and international suppliers. In response, manufacturers may reconfigure global sourcing strategies, relocate certain stages of assembly closer to demand centers, or adjust product portfolios to prioritize regions with favorable trade terms.

Operationally, laboratories and contract research providers respond to tariff-driven cost inflation by optimizing inventory management, renegotiating supplier contracts, and exploring alternative assay workflows that rely on more readily available inputs. Transitional periods following tariff implementation typically see cautious ordering behavior as buyers reassess total landed cost and evaluate the trade-offs between price, performance, and supply continuity. Regulatory considerations also intersect with tariff impacts when reagents or instruments require specific approvals; localized manufacturing can help mitigate both tariff exposure and approval lead times. Ultimately, while tariffs add a layer of complexity to procurement and pricing, organizations that proactively model supply chain scenarios and pursue supplier diversification can preserve continuity and maintain competitive pricing strategies.

In-depth segmentation analysis revealing how technology modalities applications product types and end-user profiles jointly shape commercial pathways and investment priorities

Segment-level perspectives reveal where capability, customer needs, and commercialization models intersect to create differentiated opportunities. Technology segmentation highlights the interplay between legacy platforms and emerging modalities, where Microarray remains relevant for targeted genotyping and population studies, Next Generation Sequencing drives comprehensive genomic profiling and novel applications, Polymerase Chain Reaction supports rapid diagnostics and quantitation, and Sanger Sequencing continues to serve validation and niche sequencing tasks. Each technology pathway presents distinct development cycles, regulatory considerations, and cost-performance characteristics that influence adoption trajectories.

Application segmentation shows how use cases shape product design and service delivery, with Clinical Diagnostics demanding validated workflows and reproducible analytics, Genetic Disease analyses requiring deep variant interpretation and counseling integration, Infectious Disease testing prioritizing speed and multiplexing, Oncology focusing on sensitivity for low-frequency variants and actionable biomarkers, and Reproductive Health emphasizing accuracy and ethical counseling. Product type segmentation clarifies business model implications: Consumables create recurring revenue and inventory planning complexities, Instruments involve capital expenditure and maintenance ecosystems, Services rely on operational scale and quality accreditation, and Software requires data integration, regulatory clarity, and ongoing algorithmic validation. End-user segmentation underscores the diversity of procurement and operational contexts, as Contract Research Organizations prioritize throughput and standardization, Diagnostic Laboratories focus on accreditation and clinical turnaround, Hospitals demand integration with care pathways, Pharmaceutical Companies emphasize translational research and companion diagnostics, and Research Institutes concentrate on experimental flexibility and methodological innovation. By tracing how these segment dimensions interact, stakeholders can target investments that align technical capabilities with the specific regulatory, operational, and commercial constraints of their customers.

Regional dynamics and differentiated opportunity sets across the Americas Europe Middle East & Africa and Asia-Pacific that determine strategic go-to-market and supply chain choices

Regional dynamics drive differentiated opportunity sets and risk profiles across the global genetic analysis landscape. In the Americas, mature healthcare infrastructure and established reimbursement mechanisms support advanced clinical applications, strong private investment, and a dense network of diagnostic laboratories and biopharma partners. This environment favors rapid clinical translation and commercial scale-up, while also attracting talent and capital for instrumentation and software ventures.

Across Europe, the Middle East & Africa, regulatory heterogeneity and diverse healthcare funding models create both challenges and niches for tailored solutions, with leading academic centers and specialized commercial providers advancing precision oncology and rare disease diagnostics. In the Asia-Pacific region, a combination of large population cohorts, expanding healthcare coverage, and growing domestic manufacturing capability has driven rapid adoption of both high-throughput sequencing and cost-effective PCR-based diagnostics. Regional policy incentives and local production initiatives further influence supply chain strategies, while cross-border collaborations and investment flows continue to intensify as stakeholders seek to address capacity, access, and localized clinical needs. Together, these regional characteristics require companies to adapt go-to-market strategies, regulatory approaches, and partnership models to capture opportunities effectively.

Competitive landscape insights showing how platform innovation integrated services and regulatory-aligned collaborations are determining leadership and differentiation

Competitive positioning across the genetic analysis space reflects a blend of technology leadership, integrated service capabilities, and strategic partnerships. Leading instrument manufacturers continue to invest in throughput improvements, ease of use, and consumables ecosystems that lock in recurring demand. At the same time, specialized service providers and sequencing hubs differentiate through accreditation, fast turnaround, and bioinformatics depth that translate into clinical-grade offerings for hospitals and diagnostic laboratories.

Software and algorithm developers are increasingly important as interpretation complexity grows; robust variant curation, machine learning-driven prioritization, and secure data management now sit at the core of clinical adoption. Collaborative models are also prominent, as pharmaceutical companies, academic centers, and diagnostics firms form consortia to share data and accelerate assay validation for complex indications. For organizations evaluating competitive moves, the emphasis should be on securing clinical validation pathways, establishing durable supply chains for critical consumables, and forging alliances that combine technical capabilities with market access. Those that balance platform innovation with service excellence and regulatory rigor will sustain competitive advantage.

Actionable recommendations for leaders to strengthen supply chain resilience accelerate clinical validation expand analytics capabilities and deploy flexible commercial models to capture value

Industry leaders should prioritize a set of pragmatic, high-impact actions to translate strategic intent into measurable outcomes. First, strengthen supply chain resilience by diversifying suppliers for critical reagents and components and by assessing nearshoring or regional production partnerships to reduce geopolitical and tariff exposure. Second, align product development with evidence generation that demonstrates clinical utility; invest in prospective validation studies and payer engagement to streamline reimbursement pathways and accelerate adoption.

Third, expand analytics and software capabilities to deliver clinically meaningful interpretation and seamless integration with electronic health records and laboratory information systems; this will enhance customer retention and unlock higher-value service contracts. Fourth, pursue targeted collaborations with healthcare systems and research centers to co-develop assays that meet real-world needs, thereby reducing market entry friction. Finally, build flexible commercial models that combine instrument leasing, consumable subscriptions, and outcome-based contracting to address diverse customer procurement preferences and to create predictable revenue streams. Executing these recommendations will require cross-functional governance, clear KPIs tied to clinical uptake, and investment in talent capable of navigating both regulatory and commercial complexities.

Transparent research methodology combining stakeholder interviews secondary literature synthesis and scenario-based analysis to produce validated strategic insights and actionable guidance

The research methodology underlying this analysis synthesizes primary stakeholder engagement, secondary literature review, and cross-validation with regulatory and clinical guidance to ensure robust, actionable insights. Primary input included structured interviews with laboratory directors, R&D leaders, procurement officers, and bioinformatics specialists to capture operational realities, adoption barriers, and priorities for clinical validation. These qualitative perspectives were triangulated with a systematic review of recent peer-reviewed literature, regulatory agency communications, and patent activity to verify technological trajectories and emergent use cases.

Analytical rigor was maintained through scenario-based supply chain modeling and comparative assessment of platform capabilities against clinical requirements for sensitivity, specificity, throughput, and cost per assay. Interpretative layers considered reimbursement pathways and accreditation constraints to ensure recommendations align with real-world adoption levers. Throughout the process, findings were stress-tested for plausibility and operational feasibility, while confidentiality and respondent anonymity were strictly maintained to encourage candid input from industry participants.

Concluding synthesis emphasizing the necessity of combining rigorous evidence generation resilient operations and customer-centric digital capabilities to realize the promise of genetic analysis

In synthesis, the genetic analysis domain is at the intersection of powerful technological capability and complex commercial, regulatory, and supply chain realities. Advances in sequencing, PCR, and automation have unlocked broader clinical and research applications, but long-term success hinges on demonstrating clinical utility, ensuring supply continuity, and navigating diverse regional regulatory frameworks. Organizations that integrate high-quality evidence generation with resilient operational design and customer-focused digital tools will establish durable competitive positions.

Looking ahead, the most successful players will be those that balance innovation with pragmatic execution: investing in validation studies that speak to payers and clinicians, building modular service offerings that adapt to varied end-user needs, and cultivating partnerships that bridge technical expertise with market access. By doing so, stakeholders can translate scientific promise into measurable patient impact and sustainable commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genetic Analysis Market, by Product Type

  • 8.1. Consumables
  • 8.2. Instruments
  • 8.3. Services
  • 8.4. Software

9. Genetic Analysis Market, by Technology

  • 9.1. Microarray
  • 9.2. Next Generation Sequencing
  • 9.3. Polymerase Chain Reaction
  • 9.4. Sanger Sequencing

10. Genetic Analysis Market, by Application

  • 10.1. Clinical Diagnostics
  • 10.2. Genetic Disease
  • 10.3. Infectious Disease
  • 10.4. Oncology
  • 10.5. Reproductive Health

11. Genetic Analysis Market, by End User

  • 11.1. Contract Research Organizations
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Pharmaceutical Companies
  • 11.5. Research Institutes

12. Genetic Analysis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Genetic Analysis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genetic Analysis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Genetic Analysis Market

16. China Genetic Analysis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Beam Therapeutics Inc.
  • 17.7. BGI Group
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. CRISPR Therapeutics AG
  • 17.10. Danaher Corporation
  • 17.11. Editas Medicine, Inc.
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. GenScript Biotech Corporation
  • 17.14. Illumina, Inc.
  • 17.15. Intellia Therapeutics, Inc.
  • 17.16. Merck KGaA
  • 17.17. Myriad Genetics, Inc.
  • 17.18. PerkinElmer, Inc.
  • 17.19. QIAGEN N.V.
  • 17.20. Sangamo Therapeutics, Inc.
  • 17.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENETIC ANALYSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENETIC ANALYSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GENETIC DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GENETIC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GENETIC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GCC GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. GCC GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GCC GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. G7 GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. G7 GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. G7 GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. G7 GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. G7 GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NATO GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. NATO GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NATO GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GENETIC ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA GENETIC ANALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA GENETIC ANALYSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA GENETIC ANALYSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA GENETIC ANALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA GENETIC ANALYSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)